Clinical Trials Logo
  1. Home
  2. Streptococcus Pneumoniae
  3. NCT00849069

Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine

Streptococcus Pneumoniae Clinical Trial

Official title:
An Observer-blind, Safety Study of GSK Biologicals' Haemophilus Influenzae and Streptococcus Pneumoniae Candidate Vaccine in Adults.

Clinical Trial Summary

The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK2231395A candidate vaccine in adults and elderly adults with chronic obstructive pulmonary disease. Subjects will be vaccinated 3 times with an interval of respectively 2 and 10 months.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00849069
Study type Interventional
Source GlaxoSmithKline
Contact
Status Terminated
Phase Phase 1
Start date March 12, 2009
Completion date April 7, 2009
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT02215863 - Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years Phase 4
Completed NCT01521897 - Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan) N/A
Completed NCT00197769 - Immunogenicity of a Reduced Primary Schedule for Pneumococcal Conjugate Vaccine in UK Infants Phase 2
Completed NCT02888457 - Carriage of Streptococcus Pneumoniae in Infants With Acute Otitis Media and in Infants Attending Day-care Centers N/A
Completed NCT01995617 - Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine Phase 1
Completed NCT01425372 - Evaluating Vaccine Responses in Healthy Infants Receiving Their Routine Primary Immunisation According to the Accelerated United Kingdom Schedule at 2, 3 and 4 Months
Completed NCT00594347 - Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar Phase 3
Completed NCT00861380 - Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease Phase 3
Active, not recruiting NCT00900978 - Impact of the 7 Valent Pneumococcal Conjugate Vaccine (7vPCV) on Nasopharyngeal Carriage of Streptococcus Pneumoniae in Healthy Jordanian Infants Phase 1/Phase 2
Completed NCT00814710 - Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age Phase 3
Suspended NCT01308827 - Costa Rica Epidemiological Study on S. Pneumoniae N/A
Recruiting NCT04078997 - An Evaluation of PCV13 Vaccine Schedules, Comparing Impact of 2+1 vs 3+0 on Pneumococcal Carriage in Blantyre, Malawi
Recruiting NCT06096025 - Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream Infections
Completed NCT00907777 - Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™ Phase 3
Completed NCT00273325 - Immunogenicity of PCV-7 Vaccine in VLBW Infants
Completed NCT00814489 - Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults Phase 1
Completed NCT01730391 - Neisseria Meningitidis Burden of Disease Study N/A
Completed NCT00197821 - Evaluation of the Immunogenicity and Reactogenicity of a Pneumococcal Conjugate Vaccine in Healthy Adults Phase 2
Completed NCT00839254 - Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Phase 3